Nura Bio has completed a $73.8 million Series B financing round as it advances its pipeline of SARM1 inhibitors. 

The financing, led by The Column Group, is set to fund the development of Nura Bio’s clinical pipeline, including the Phase Ib/IIa study of NB-4746, an oral, brain-penetrant SARM1 inhibitor. 

NB-4746 has been shown to prevent axon degeneration driven by the SARM1 protein, providing neuroprotection in multiple preclinical models of nerve injury and disease, including ALS.  

In a Phase I study in healthy volunteers, NB-4746 demonstrated a favourable safety profile and achieved target plasma and cerebrospinal fluid exposure levels.  

Nura Bio has also commenced dosing of an oral, covalent, allosteric SARM1 inhibitor, NB-9402, in a first-in-human study. NB-9402 has demonstrated high potency and long-lasting efficacy in preclinical models of neurological diseases. 

“With NB-4746 actively enrolling ALS patients in a Phase Ib/IIa study and the rapid advancement of NB-9402, our next generation covalent allosteric SARM1 inhibitor, into a Phase Ia study, we have built a portfolio of SARM1 inhibitors uniquely positioned to fully explore and validate the broad therapeutic potential of this target,” said Shilpa Sambashivan, CEO of Nura Bio.  

“This progress reinforces our commitment to pursuing ground-breaking science and developing transformative therapies for people with life-threatening neurological diseases.”